NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, reported financial results for the fiscal year ended December 31, 2023. The company, which focuses on developing treatments for neurodegenerative diseases, including ALS, AD, and PD, incurred a net loss of $11.28 million for the year, compared to a net loss of $12.34 million in the previous year. The accumulated deficit as of December 31, 2023, was $32.06 million. NeuroSense's lead product candidate, PrimeC, designed to treat ALS, has been granted orphan drug designation by the FDA and EMA. The company's Phase 2b trial, PARADIGM, met primary safety and tolerability endpoints, with positive clinical efficacy signals. NeuroSense expects to initiate a pivotal clinical trial for PrimeC by the end of 2024. The company has not generated revenue and does...Show More

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, reported financial results for the fiscal year ended December 31, 2023. The company, which focuses on developing treatments for neurodegenerative diseases, including ALS, AD, and PD, incurred a net loss of $11.28 million for the year, compared to a net loss of $12.34 million in the previous year. The accumulated deficit as of December 31, 2023, was $32.06 million. NeuroSense's lead product candidate, PrimeC, designed to treat ALS, has been granted orphan drug designation by the FDA and EMA. The company's Phase 2b trial, PARADIGM, met primary safety and tolerability endpoints, with positive clinical efficacy signals. NeuroSense expects to initiate a pivotal clinical trial for PrimeC by the end of 2024. The company has not generated revenue and does not expect to do so in the near future, as it continues to invest in research and development. Operating expenses primarily include research and development costs, general and administrative expenses, and costs associated with maintaining compliance with regulatory standards. NeuroSense is subject to various legal proceedings and claims in the ordinary course of business but does not currently face any that are expected to have a material adverse effect on its operations. The company's financial position may be impacted by fluctuations in foreign currency exchange rates, particularly between the U.S. Dollar and the New Israeli Shekel.